Table 1.
Clinical research of targeting GLS [127]
| Mainly targets | ClinicalTrials.gov Identifier | Phase | First posted | Drug | Combination drugs |
|---|---|---|---|---|---|
| TNBC, NSCLC, renal cell carcinoma | NCT02071862 | 1 | 2014 | CB-839 (Telaglenastat) | – |
| CRC | NCT03263429 | 1/2 | 2017 | CB-839 | Panitumumab and irinotecan |
| AML | NCT03047993 | 1/2 | 2017 | CB-839 | Azacitidine |
| Hematological tumors | NCT02071888 | 1 | 2014 | CB-839 | – |
| Clear cell renal cell carcinoma, melanoma, NSCLC | NCT02771626 | 1/2 | 2016 | CB-839 | Nivolumab |
| NSCLC, CRC | NCT03965845 | 1/2 | 2019 | CB-839 | Palbociclib |
| Clear cell renal cell carcinoma, TNBC | NCT03875313 | 1/2 | 2019 | CB-839 | Talazoparib |
| NSCLC | NCT04265534 | 2 | 2020 | CB-839 | Pembrolizumab |
| TBNC | NCT03057600 | 2 | 2017 | CB-839 | Paclitaxel-carboplatin |
| Metastatic prostate cancer | NCT04824937 | 2 | 2021 | CB-839 | – |
| AML, ALL | NCT02071927 | 1 | 2018 | CB-839 | Azacitidine |
| Ovarian cancer | NCT03944902 | 1 | 2019 | CB-839 | Niraparib |
| Advanced renal cell carcinoma, metastatic renal cell carcinoma | NCT03428217 | 2 | 2018 | CB-839 | Cabozantinib |
| Malignant peripheral nerve sheath tumors | NCT03872427 | 2 | 2019 | Telaglenastat hydrochloride | – |
| Leptomeningeal neoplasm, metastatic lung non-small cell carcinoma, metastatic malignant neoplasm in the brain | NCT04250545 | 1 | 2020 | Telaglenastat hydrochloride | – |
| Plasma cell myeloma | NCT03798678 | 1 | 2019 | Telaglenastat hydrochloride | Carfilzomib dexamethasone |
| Astrocytoma | NCT03528642 | 1 | 2019 | Telaglenastat hydrochloride | Temozolomide |
| NSCLC | NCT03831932 | 1 | 2019 | Telaglenastat hydrochloride | Osimertinib |
TNBC triple negative breast cancer, NSCLC non-small cell lung cancer, CRC colorectal carcinoma, AML acute myeloid leukemia, ALL acute lymphocytic leukemia